Related by context. All words. (Click for frequent words.) 71 macrovascular events 69 ATACAND 69 CVD mortality 69 antihypertensive therapy 69 cardiovascular mortality 68 serum triglycerides 68 serum cholesterol 68 serum uric acid 68 β blockers 67 lipid levels 67 macrovascular 67 glycated hemoglobin levels 67 hyperglycaemia 67 symptomatic VTE 67 atherothrombotic events 67 HMG CoA reductase inhibitors 66 candesartan 66 candesartan cilexetil 66 systolic hypertension 66 thrombotic events 66 antioxidant supplementation 66 autoantibody levels 66 dyslipidaemia 66 Combination therapy 66 CETP inhibition 66 chromium supplementation 66 lowering LDL cholesterol 66 elevated triglycerides 66 cardiovascular hospitalization 65 nephrotoxicity 65 ACE inhibitor ramipril 65 lipid lowering agents 65 reinfarction 65 cardiovascular disease CVD 65 Candesartan 65 eplerenone 65 plasma lipids 65 tHcy 65 elevated LDL cholesterol 65 atherogenic dyslipidemia 65 postprandial glycemia 65 cardioprotective effects 65 platelet inhibition 65 metformin sulfonylurea 65 mixed hyperlipidemia 65 macrovascular disease 65 nonfatal MI 65 lipid abnormalities 65 colorectal adenoma 65 NATRECOR ® 65 insulin sensitizing 65 statin therapy 65 KIF6 carriers 65 CTAP# Capsules 65 hyperphenylalaninemia HPA due 65 lipid lowering therapies 64 testosterone supplementation 64 LDL lowering 64 NATRECOR R 64 paricalcitol 64 fluvastatin 64 intima media thickness 64 elevated triglyceride levels 64 Erythropoietic therapies may 64 Lp PLA2 64 glycosylated hemoglobin HbA1c 64 BENICAR HCT 64 metabolic parameters 64 calcium supplementation 64 cardio protective 64 ischemic cardiovascular 64 ivabradine 64 COPD exacerbations 64 serum phosphate 64 postoperative AF 64 glycemia 64 antiplatelet drugs 64 lipid parameters 64 coadministration 64 LDL cholesterol concentrations 64 antiplatelet agent 64 benazepril 64 recurrent venous thromboembolism 64 cardiovascular hospitalizations 64 hsCRP 64 myocardial infarction MI 64 antithrombotic 64 myocardial infarction stroke 64 olmesartan 64 riociguat 64 subclinical atherosclerosis 64 nonfatal stroke 64 statin medications 64 thromboembolic complications 64 serum leptin 64 cardiometabolic risk 64 cardiovascular disease 64 microvascular complications 64 secondary hyperparathyroidism 64 homocysteine concentrations 64 hyperphosphatemia 63 serum lipids 63 perioperative morbidity 63 angiotensin receptor blocker ARB 63 serum calcium levels 63 vascular inflammation 63 morphometric vertebral fractures 63 plasma triglycerides 63 carotid IMT 63 beta carotene supplementation 63 valsartan 63 angiotensin II receptor blockers 63 serum calcium 63 tocilizumab 63 glycosylated hemoglobin levels 63 triglyceride lowering 63 lipid profiles 63 nondiabetic patients 63 #.#/#.# mmHg [001] 63 antidiabetic drug 63 serum urate 63 antidiabetic drugs 63 lipid lowering therapy 63 lipid lowering 63 adenoma recurrence 63 strontium ranelate 63 HbA1c levels 63 Statin therapy 63 prostate cancer CaP 63 tolvaptan 63 secondary efficacy endpoints 63 dosing frequency 63 ACTEMRA TM 63 LDL cholesterol lowering 63 lowering blood glucose 63 MICARDIS ® 63 clinically meaningful reductions 63 serum phosphate levels 63 Trandolapril 63 glitazones 63 primary hypercholesterolemia 63 hypercholesterolemia 63 serum phosphorous 63 LHRH antagonists 63 STRIDE PD 63 contrast induced nephropathy 63 posaconazole 63 extrapyramidal symptoms 63 polyp recurrence 62 vidofludimus 62 prostate carcinogenesis 62 RoACTEMRA 62 thrombotic complications 62 irbesartan 62 EDARBI 62 oral antidiabetic medication 62 atherosclerotic disease 62 glucose lowering 62 NIASPAN 62 Atacand 62 BENICAR 62 metastatic castration resistant 62 hypercholesterolaemia 62 Lp PLA 2 62 cardiac dysfunction 62 CRESTOR #mg 62 serum vitamin D 62 Fondaparinux 62 recurrent myocardial infarction 62 recurrent VTE 62 H. pylori eradication 62 lowering triglycerides 62 macrovascular complications 62 Rasilez Tekturna 62 venous thromboembolic events 62 biologic plausibility 62 nonfatal myocardial infarction 62 antitumor effect 62 antidiabetic 62 rosuvastatin #mg 62 NPH insulin 62 thiazide diuretics 62 rosuvastatin 62 intensive lipid lowering 62 postoperative mortality 62 antiplatelet therapies 62 angiotensin converting enzyme inhibitor 62 ExTRACT TIMI 62 Nesiritide 62 myopathy rhabdomyolysis 62 diabetic kidney 62 Primary endpoints 62 apo B 62 salmeterol fluticasone 62 HDL C 62 AEGR 62 nonalcoholic steatohepatitis NASH 62 periprocedural 62 thiazolidinedione 62 abdominal adiposity 62 ABCB1 62 liver histology 62 mycophenolate mofetil 62 teriflunomide 62 upper gastrointestinal bleeding 62 hemoglobin A1c levels 62 pulmonary exacerbations 62 platelet reactivity 62 bezafibrate 62 magnesium intake 62 cinacalcet 62 apolipoprotein B 62 leukotriene pathway 62 serum phosphorus 62 elevated homocysteine 62 atherogenic 62 nonfasting triglyceride levels 62 ezetimibe Zetia 62 SERMs 62 acarbose 62 antiangiogenic therapy 62 thromboxane A2 62 HbA 1c 62 serum lipid levels 62 LDL oxidation 61 diabetes dyslipidemia 61 Procoralan 61 lipoprotein Lp 61 morbidity mortality 61 desvenlafaxine succinate 61 GP IIb IIIa inhibitors 61 eprotirome 61 nonfasting triglycerides 61 poststroke depression 61 chronic thromboembolic pulmonary 61 ALB # 61 azacitidine 61 atherosclerotic vascular disease 61 deferiprone 61 intensive statin therapy 61 hemorrhagic complications 61 PEGylated interferon beta 1a 61 renal toxicity 61 selenium supplementation 61 abacavir lamivudine 61 flecainide 61 AZOR 61 perinatal morbidity 61 probiotic supplementation 61 Celecoxib 61 Valsartan 61 vildagliptin 61 ApoA1 61 vitamin D supplementation 61 PSN# [002] 61 serum potassium 61 HIV HCV coinfected 61 direct thrombin inhibitors 61 HMG CoA reductase inhibitor 61 thromboembolic disease 61 Telmisartan 61 Thiazolidinediones 61 aldosterone antagonists 61 thiazide diuretic 61 oral antidiabetic drugs 61 Cimzia TM 61 ramipril 61 C reactive protein 61 oxcarbazepine 61 CYP #A# 61 cardiotoxicity 61 DU #b 61 quetiapine Seroquel 61 pravastatin Pravachol 61 xanthine oxidase inhibitor 61 arterial calcification 61 Adjuvant chemotherapy 61 AA Amyloidosis 61 rolofylline 61 allopurinol 61 APTIVUS r 61 cranial irradiation 61 ruboxistaurin 61 secondary efficacy endpoint 61 myocardial reperfusion 61 plasma lipid 61 locoregional recurrence 61 antidepressant efficacy 61 tumor lysis syndrome 61 postmenopausal breast cancer 61 serum urate levels 61 antiplatelet 61 metabolic abnormalities 61 flutamide 61 oral rivaroxaban 61 LDL cholesterol levels 61 PAOD 61 uric acid levels 61 Darapladib 61 ARIXTRA 61 EFFEXOR XR 61 leukotriene receptor antagonists 61 INCB# [003] 61 statin simvastatin 61 carotid plaque 61 antihypertensive medications 61 hypertensive patients 61 muraglitazar 61 angiotensin receptor blockers 61 atherothrombotic 61 carotid intima media 61 antiplatelet medications 61 triglyceride concentrations 61 antihypertensive therapies 61 LDL C 61 LV dysfunction 61 carotid atherosclerosis 61 Calcium intake 61 elevated CRP 61 intact parathyroid hormone 61 serum triglyceride levels 61 endometrial hyperplasia 61 subclinical hypothyroidism 61 interferon beta therapy 61 atherogenic lipids 61 HDL Cholesterol 61 antihypertensive agents 61 NYHA Class II 61 ULORIC 61 selective modulator 61 levosimendan 61 cholesterol LDL C 61 goserelin 61 bicalutamide 61 canakinumab 61 antihypertensive drugs 61 thyrotropin 61 ARCOXIA 61 Pioglitazone 61 TZDs 61 statins 61 thetreatment 61 angiotensin converting enzyme inhibitors 61 CYT# potent vascular disrupting 61 clinically meaningful 61 plasma renin activity 61 ximelagatran 61 anticoagulant warfarin 61 COREG 61 venlafaxine Effexor 61 recurrent glioblastoma multiforme 61 Tekamlo 61 bosentan 61 antiarrhythmic 61 carvedilol 61 dose atorvastatin 61 primidone 61 angiotensin receptor blockers ARBs 61 thromboembolic 61 elotuzumab 61 chlorthalidone 61 DULERA 61 QTc intervals 61 urinary oxalate 61 Carvedilol 61 folate supplementation 61 beta blocker therapy 61 atherothrombotic disease 61 composite endpoint 61 Tavocept 61 fasting glucose levels 61 TNF Tumor Necrosis Factor 61 PRT# 61 antihypertensive medication 61 coronary heart 61 IIIa inhibitor 60 thiazolidinediones 60 Natalizumab 60 hypercalciuria 60 severe renal insufficiency 60 LDL Cholesterol 60 elevated uric acid 60 sorafenib Nexavar 60 Tolvaptan 60 uric acid lowering 60 cardiovascular disease hypertension 60 microalbuminuria 60 atherosclerosis 60 Cleviprex TM clevidipine 60 vasomotor symptoms 60 inflammatory biomarkers 60 pioglitazone HCl 60 anti leukemic 60 ACEIs 60 NSAID associated 60 HbA1C 60 Elevated triglycerides 60 fosamprenavir 60 atherosclerotic 60 surrogate endpoint 60 RE LY ® 60 oral diclofenac 60 cardiac toxicity 60 rimonabant #mg 60 fasting triglycerides 60 left ventricular dysfunction 60 improves insulin sensitivity 60 Virulizin ® 60 lipid lowering drugs 60 ACE Inhibitor 60 nicardipine 60 pertuzumab 60 recurrent ischemia 60 oral anticoagulation 60 abnormal lipids 60 A2 Lp PLA2 60 plasma pharmacokinetics 60 RBP4 levels 60 albuminuria 60 vasodilatation 60 T2DM 60 pyridostigmine 60 fatal IHD 60 imatinib therapy 60 INTEGRILIN 60 non valvular atrial 60 verapamil 60 pioglitazone 60 hepatotoxicity 60 Aceon 60 velafermin 60 lowering triglyceride levels 60 aripiprazole Abilify 60 serum lipid 60 PRADAXA 60 infliximab Remicade 60 eosinophil count 60 cardioprotective effect 60 pulmonary toxicity 60 reperfusion injury 60 abnormal glucose tolerance 60 albumin excretion 60 alagebrium 60 Diovan HCT 60 AVANDIA 60 serum PSA 60 antiplatelet therapy 60 aspirin clopidogrel 60 paroxetine Paxil 60 serum BDNF 60 thienopyridines 60 thromboembolic events 60 relapsed MM 60 diastolic BP 60 FOSRENOL ® 60 folate intake 60 serum biomarkers 60 preserved ejection fraction 60 variceal bleeding 60 ZD# [001] 60 leukotriene B4 60 Micardis ® 60 SIMCOR 60 androgen deprivation 60 ventricular remodeling 60 RLY# 60 insulin glargine 60 PREZISTA r 60 angiotensin II receptor blocker 60 oral anticoagulant 60 arterial stiffness 60 CLA supplementation 60 Epanova 60 mitochondrial toxicity 60 platelet activation 60 beta blocker atenolol 60 onset diabetes mellitus 60 sUA 60 erythropoietic 60 CIMZIA ™ 60 PRISTIQ 60 cirrhosis liver failure 60 lipoprotein metabolism 60 paclitaxel eluting stents 60 diabetes hyperlipidemia 60 nalbuphine ER 60 protein excretion 60 glycemic variability 60 zoledronate 60 MULTAQ 60 oral prodrug 60 vasodilators 60 colesevelam HCl 60 endothelial activation 60 serum PTH 60 lumiracoxib 60 chronic periodontitis 60 somatostatin analog 60 alteplase 60 bronchial hyperresponsiveness 60 zonisamide SR 60 dyslipidemia 60 VLDL cholesterol 60 tecarfarin 60 coinfected patients 60 TRILIPIX 60 hepatic fibrosis 60 AVAPRO 60 glycated hemoglobin HbA1c 60 mg BID dose 60 diabetic gastroparesis 60 biphasic insulin aspart 60 symptomatic intracranial hemorrhage 60 Pazopanib 60 hypertensives 60 serum parathyroid hormone 60 aliskiren 60 hyperkalemia 60 density lipoprotein HDL cholesterol 60 ARIMIDEX 60 Proteinuria 60 sulphonylureas 60 perioperatively 60 variant angina 60 varespladib 60 antidiabetic therapy 60 hydroxyvitamin D levels 60 hydroxymethyl coenzyme 60 systemic immunosuppressive drugs 60 hypercalcaemia 60 MAGE A3 ASCI 60 AST ALT 60 evaluating tivozanib 60 FASLODEX 60 pain palliation 60 rosuvastatin Crestor 60 statins cholesterol lowering 60 glomerular filtration 60 A1c levels 60 antitumor effects 60 myocardial ischemia 60 dysglycemia 60 antiarrhythmic drug 60 Vidofludimus 60 NSAID induced 60 oral Xeloda 60 BYETTA exenatide injection 60 H2 blocker 60 pravastatin therapy 60 atorvastatin Lipitor 60 proteinuria 60 dose dependently 60 diastolic blood pressures 60 pCR 60 thromboembolism 60 blood glucose concentrations 60 cilostazol 60 lipoprotein levels 60 fasting plasma glucose 60 Mg Uk 60 elevated intraocular pressure 60 Dasatinib 60 renoprotective 60 adiponectin levels 60 tiotropium 60 Ranolazine 60 efficacy endpoint 60 coronary artery atherosclerosis 60 Ophena TM 60 Crestor rosuvastatin 60 periprocedural MI 60 Ramipril 60 HDL2 60 GnRH agonists 60 interferon alfa 2b 60 tirofiban 60 Xanafide 59 potentially modifiable 59 lispro 59 neurologic progression 59 lipid lowering medications 59 postoperative atrial fibrillation 59 HoFH 59 KOMBIGLYZE XR 59 5 HT6 receptor 59 ApoB 59 antithrombotics 59 microvascular disease 59 edifoligide 59 serum concentrations 59 Ascherio 59 pramlintide 59 insulin sensitizers 59 resistant hypertension 59 TAXUS Express Stent 59 Aliskiren 59 sustained virological response 59 urinary excretion 59 ADHF 59 MAO B 59 Vidaza azacitidine 59 arterial inflammation 59 liver transplant recipients 59 triglycerides TG 59 HuLuc# 59 pioglitazone Actos 59 immune modulating 59 cobiprostone 59 induce orthostatic hypotension 59 headache nasopharyngitis 59 inflammatory markers 59 blood lipids 59 HBeAg negative 59 Angiotensin converting enzyme 59 erlotinib Tarceva ® 59 Subgroup analyzes 59 platelet function 59 Celecoxib APC trial 59 HeFH 59 ezetimibe simvastatin 59 symptomatic intracranial 59 dopaminergic therapy 59 recurrent DVT 59 beta blockers ACE inhibitors 59 intravenous bisphosphonates 59 APTIVUS 59 impaired glucose metabolism 59 VADT 59 cerebral infarction 59 darapladib 59 dose colchicine 59 Randomized trials 59 hepatotoxic 59 lowers triglycerides 59 peptide BNP 59 UACR 59 sodium glucose cotransporter 59 nonvertebral fractures 59 forodesine 59 systemic embolism 59 GFT# 59 transferrin saturation 59 binary restenosis 59 PIGF 59 metabolic disturbances 59 paroxetine sertraline 59 Topiramate 59 erlotinib Tarceva 59 PrandiMet TM 59 phosphate binders 59 RBP4 59 thiazolidinedione TZD 59 beclomethasone dipropionate 59 lipid elevations 59 Microalbuminuria 59 hepatic toxicity 59 antianginal 59 urate levels 59 ACCORD Lipid 59 ancrod 59 Tiotropium 59 fluoxetine Prozac 59 AIM HIGH 59 lupus nephritis 59 Prestara 59 thickness CIMT 59 neuroregenerative 59 intracerebral haemorrhage 59 lomitapide 59 angiographic outcomes 59 platelet inhibitor 59 oral antidiabetic 59 NSTE ACS 59 myocardial infarction 59 spontaneous preterm delivery 59 Navelbine 59 Prilosec omeprazole 59 rFVIIa 59 pegylated liposomal doxorubicin 59 dose clopidogrel 59 tamoxifen Nolvadex ® 59 hemoglobin A1c HbA1c 59 Protelos 59 risperidone Risperdal 59 nocturnal hypoglycaemia 59 thyrotropin levels 59 Inhaled corticosteroids 59 inhaled glucocorticoids 59 renal dysfunction 59 aminotransferases 59 torsemide ER 59 Bosentan 59 plasma kallikrein inhibitor 59 calcium antagonists 59 CIMZIA TM certolizumab pegol 59 coronary atherosclerosis 59 infarct size 59 parecoxib 59 avosentan 59 fondaparinux 59 invasive candidiasis 59 recurrent genital herpes 59 Abbott Trilipix 59 antihypertensives 59 prognostic indicators 59 prospectively defined 59 sotalol 59 adrenal suppression 59 noncardiovascular mortality 59 mecamylamine 59 exploratory endpoints 59 distal colon cancer 59 dietary modification 59 Epidemiologic studies 59 antiarrhythmic drugs 59 serum LDL cholesterol 59 metabolic acidosis 59 Hyperlipidemia 59 telmisartan 59 unfractionated heparin UFH 59 left ventricular diastolic 59 tiotropium bromide 59 prognostic indicator 59 interferon gamma 1b 59 Thal Dex 59 losartan Cozaar 59 PLX STROKE targeting 59 insulin detemir 59 atherosclerotic progression 59 ischemic cardiomyopathy 59 mixed dyslipidemia 59 CHD coronary 59 collagen degradation 59 Elocalcitol 59 senicapoc 59 ACTOS 59 chemopreventive agent 59 Uncontrolled hypertension 59 therapeutic regimens 59 factor Xa inhibitor 59 overt hepatic encephalopathy HE 59 immunosuppressive regimen 59 CaPre TM 59 H2 receptor antagonists 59 elevated fasting glucose 59 central adiposity 59 nonfatal myocardial infarction MI 59 maximally tolerated doses 59 HF hospitalization 59 T1DM 59 RE LY 59 anti fibrotic 59 bile acid sequestrant 59 Exacerbations 59 Duloxetine 59 Secondary efficacy endpoints 59 apoB 59 c reactive protein 59 thiazolidinediones TZDs 59 HDL cholesterol triglycerides 59 sitaxsentan 59 CYP#D# inhibitor 59 postoperative morbidity 59 Femara letrozole 59 davalintide 59 lanthanum carbonate 59 fasting plasma glucose FPG 59 Non Alcoholic Steatohepatitis 59 decitabine 59 ELND# 59 ticagrelor 59 pramlintide metreleptin combination 59 prednisone prednisolone 59 antihypertensive 59 myocardial infarctions 59 Fibrates 59 Cardiopulmonary bypass 59 β blocker 59 unresectable tumors 59 #.#mg/dL 59 LY# [003] 59 basal bolus regimen 59 perindopril 59 methotrexate MTX 59 HbA1C levels 59 obese postmenopausal 59 RNAi therapeutic targeting PCSK9 59 schizophrenia CIAS 59 fasting plasma 59 EXJADE 59 tranylcypromine 59 metformin 59 triacylglycerol concentrations 59 prostate cancer PCa 59 protease inhibitor PI 59 * olmesartan medoxomil 59 Tyrima 59 shorter telomere length 59 brivaracetam 59 Zemplar Capsules 59 non fasting triglycerides 59 Events MACE 59 LANTUS ® 59 TNF antagonist 59 T2D 59 psoriatic arthritis PsA 59 FUSILEV enhances 59 Lenalidomide 59 somatostatin analogs 59 Vitamin D supplementation 59 homocysteine levels 59 elevated IOP 59 Endothelial dysfunction 59 artery stenosis 59 fibrinolysis 59 oral FTY# 59 eptifibatide 59 thromboprophylaxis 59 dyslipidemias 59 interleukin IL -6 59 myeloperoxidase 59 adalimumab 59 overt nephropathy 59 HER2 overexpression 59 Androgen deprivation therapy 59 idraparinux 59 SSc 59 clodronate 59 Egrifta 59 vWF 59 salmeterol inhalation powder 59 Panzem R 59 XIENCE V PROMUS Stent 59 pharmacokinetic PK profile 59 pentoxifylline 59 haloperidol Haldol 59 serum glucose 59 selenium intake 59 alpha blocker 59 Celebrex celecoxib 59 left ventricular hypertrophy 59 carotid plaques 58 hyperinsulinemia 58 VIIBRYD 58 antithrombotic therapy 58 Paxil paroxetine 58 bioavailable testosterone 58 SHPT 58 cediranib 58 hyperhomocysteinemia 58 antiplatelet agents 58 dietary antioxidants 58 Pseudomonas aeruginosa infections 58 ELACYT 58 mTOR kinase 58 potassium sparing diuretics 58 death reinfarction 58 FOSRENOL R 58 CBLC# 58 pan HDAC inhibitor 58 risedronate Actonel 58 micafungin 58 draining enterocutaneous 58 Diabetic nephropathy 58 bivalirudin 58 BYSTOLIC 58 EMPOWER ™ 58 Mevacor lovastatin 58 aromatase inhibitors AIs 58 advanced adenoma 58 trials RCTs 58 familial hypercholesterolemia FH 58 Syncria R 58 MEND CABG 58 antigen PSA levels 58 estramustine 58 HER2 expression 58 HNSCC 58 acute humoral rejection 58 renal insufficiency 58 APPRAISE 58 anti androgen 58 OHR/AVR# 58 metformin sulphonylurea 58 olaparib 58 purpura ITP 58 Androxal TM 58 MERLIN TIMI 58 Hypertriglyceridemia 58 inflammatory rheumatic 58 metaglidasen 58 hour bronchodilation 58 Homocysteine 58 tibolone 58 FRAGMIN 58 rosiglitazone Avandia 58 calcineurin inhibitors 58 juvenile idiopathic arthritis JIA 58 urinary calcium 58 carotid artery intima media 58 atopic disease 58 ACE inhibitors 58 sorafenib tablets 58 receptor inhibitor 58 androgen deficiency 58 standard chemotherapy regimen 58 antitumor efficacy 58 oxaliplatin Eloxatin 58 fatal myocardial infarction 58 Lubiprostone 58 Olmesartan 58 factor Xa 58 gemifloxacin 58 fibrate 58 tolerability profiles 58 Interferon beta 1b 58 Low density lipoprotein 58 surrogate marker 58 dual endothelin receptor antagonist 58 metformin Glucophage 58 diabetic neuropathic pain 58 hsCRP levels 58 CaPre ™ 58 density lipoprotein cholesterol 58 venous thromboembolism 58 Insulin detemir 58 MAXALT 58 Non inferiority 58 hyperlipidemia 58 #mg/day [002] 58 ® pioglitazone HCl 58 B vitamin supplementation 58 cardiovascular calcification 58 adalimumab Humira 58 coronary stenosis 58 orlistat Xenical 58 flavanol rich foods 58 amlodipine 58 metabolic syndrome MetS 58 IV bisphosphonates 58 LOVENOX 58 modifiable risk 58 topical calcineurin inhibitors 58 Doxil ® 58 nicotinic acid 58 Dabigatran etexilate 58 gemcitabine Gemzar 58 ziprasidone Geodon 58 prolactin levels 58 virologic response 58 hemodilution 58 ramipril Altace 58 rheumatoid arthritis osteoarthritis ankylosing 58 RE LY trial 58 echocardiographic parameters 58 #mg/dL [001] 58 adiposity 58 thalidomide Thalomid 58 Zoledronic acid 58 neonatal morbidity 58 TREDAPTIVE 58 cardiac repolarization 58 Alpha lipoic acid 58 molecular weight heparins 58 serum folate concentrations 58 cerebral perfusion 58 R lenalidomide 58 systemic corticosteroid 58 tiagabine 58 cefepime 58 galiximab 58 symptomatic hyponatremia 58 mucosal healing 58 QNEXA 58 severe exacerbations 58 cardiometabolic disorders 58 KRN# 58 albumin excretion rate 58 amifostine 58 sibutramine Meridia 58 PCWP 58 glycemic control 58 rabeprazole 58 K ras mutations 58 PPAR gamma agonists 58 atrasentan 58 relapsed SCLC 58 Subgroup analysis 58 lowering homocysteine 58 vaso occlusive crisis 58 Degarelix 58 LYSTEDA 58 cystatin C 58 plasma lipoprotein 58 lenalidomide Revlimid R 58 Symadex 58 HDL LDL ratio 58 preventing venous thromboembolism 58 CYP#A# CYP#D#